New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
Key Highlights
- ➤STORM-PE wearable data significantly correlated daily activity with 30-day six-minute walk performance
- ➤CAVT plus anticoagulation improved right ventricular recovery versus anticoagulation alone
- ➤CAVT-treated patients walked farther and more often achieved NYHA Class I
- ➤STRIKE-PE interim analysis covered 1,000 patients’ one-year functional and quality-of-life outcomes
- ➤STRIKE-PE reported sustained lower dyspnea, longer walking distance, and improved quality of life
Expert Statements
Robert Lookstein, M.D., MSc, Global co-principal investigator of the STORM-PE RCT and professor of radiology and surgery at the Icahn School of Medicine at Mount Sinai
“STORM-PE is the first RCT in pulmonary embolism therapy to incorporate data from a consumer wearable device, representing an important step forward in understanding how office assessed clinical improvements translate into meaningful real-world recovery”
Robert Lookstein, M.D., MSc, Global co-principal investigator of the STORM-PE RCT and professor of radiology and surgery at the Icahn School of Medicine at Mount Sinai
“This innovation enables the scientific community to determine whether improvements observed during office assessments are reflected in patients' real-world experiences at home.”
Rachel Rosovsky, M.D., MPH, Global co-principal investigator of the STORM-PE RCT, hematologist at Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School
“This STORM-PE subset gives us a more complete picture of patient recovery by allowing us to compare data collected in the clinic with information gathered as patients go about their daily lives”
Rachel Rosovsky, M.D., MPH, Global co-principal investigator of the STORM-PE RCT, hematologist at Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School
“By generating a more comprehensive view of patient outcomes, these findings have the potential not only to advance our understanding of the role of endovascular therapy in PE, but also to help shape the design of future clinical trials.”
James F. Benenati, M.D., FSIR, Chief medical officer at Penumbra
“At Penumbra, we are committed to advancing innovations that are supported by rigorous clinical evidence.”
James F. Benenati, M.D., FSIR, Chief medical officer at Penumbra
“By incorporating consumer wearables into STORM-PE, we have a unique opportunity to evaluate whether the clinical improvements observed in traditional assessments are reflected in patients' day-to-day recovery at home.”
James F. Benenati, M.D., FSIR, Chief medical officer at Penumbra
“Together with emerging data from STRIKE-PE, these findings contribute to a growing body of evidence supporting a significant role for CAVT in the treatment of PE.”
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism PR Newswire
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recovery
Get started
Create a free account to read the full story.